feelings of dryness at the base of the penis, around the testicles, under the foreskin, around the glans of the penis and in the anus. Discussions were also had about changes in the volume and consistency of seminal fluid released either prior to or during ejaculation. Another conversation theme revolved around how the symptoms they experienced affected their ability to engage in sexual intercourse. Forum users discussed how pain and dryness made sexual intercourse painful, resulting in them withdrawing from sexual activity indefinitely. Discussions were also had about the lack of information available to help understand and manage sexual dysfunction. Forum users discussed how feelings of embarrassment about the nature of the symptoms and the stigma of it being “a woman’s disease” kept them from seeking medical assistance. Those who had sought medical assistance shared their belief that health professionals (HPs) were misdiagnosing their symptoms and were prescribing ineffective treatments. They also reported that their HPs were dismissive of symptoms and unwilling to assist further.

**Conclusion:** Utilising conversations from an internet forum was an effective method to gain insight into some of the issues that males with SS experience with sexual functioning. The absence of accessible information and lack of support from HPs to use to gain insight into some of the issues that males with SS experience is hinted at in this research. Future research should focus on identifying issues surrounding male sexual functioning as this will both guide future intervention strategies and allow HPs to publish material to better support males with SS.

**References:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2020-eular.3698

---

**SAT0634-HPR**

**PATIENT-REPORTED OUTCOMES REGARDING TWO FORMS OF METHOTREXATE AUTOINJECTORS IN RHEUMATOID ARTHRITIS: AN INTERNATIONAL CROSS-OVER SURVEY.**

Y. Morvan, J. D. Zeitoun, I. IPSOS Healthcare, Paris, France; S. Saint-Antoine Hospital Assistance Publique Hôpitaux de Paris, Gastroenterology and Nutrition, Paris, France

**Background:** Several forms of methotrexate (MTX) autoinjectors (AI) are currently marketed in rheumatoid arthritis (RA), yet comparative data are scarce.

**Objectives:** Investigate respective perceptions of patients regarding two marketed forms of MTX AI via a survey conducted by a global market research company.

**Methods:** Patients with moderate to severe RA treated by one of the two forms of MTX AI were recruited. In each participating country (France, Ireland, United-Kingdom, Spain), the respective proportions of recruited patients were approximately aligned on local market shares. The two investigated devices were: A-AI/ The first MTX AI marketed in Europe: bigger size, with an activation button, without double injection sound-control, with a larger window; B-AI/ The second MTX AI commercialized in Europe: smaller and thinner size, without activation button, with double injection sound-control and a smaller window. Each patient was interviewed during 30 minutes on his or her satisfaction level with the currently used device. Then, they were presented the alternative AI and they could test it on skin-mimicking pads. After this step, the patients were interviewed on the alternative device.

**Results:** 100 patients were enrolled over one-month period (A-AI users, n=65; B-AI users, n=35). Overall, 61% of A-AI users reported that B-AI was “better” or “much better” whereas 43% of B-AI users judged A-AI as “better” or “much better”; When B-AI users were asked to evaluate convenience elements of A-AI, recognition of injection ending, general design and ease of use were the indicators that were the most poorly judged (60%, 54%, and 46% respectively). When A-AI users were cross-tested for B-AI, injection mode, general feeling, and ease of use were the three items providing the greatest satisfaction (80%, 77%, and 75% respectively). When they were asked about the characteristics of their usual device, the button, the design of the device and discomfort associated with the injection were the most dissatisfactory elements (30%, 31%, and 34% respectively). Also, 73% of A-AI users reported being interested in trying B-AI while 26% of B-AI users replied being so. Last, 95% of B-AI users declared being “very satisfied” or “totally satisfied”, with ease of use, number of injections, and design of injection ending being the most attractive items (94% and 95% of high or full satisfaction respectively).

**Conclusion:** In this international cross-over survey, the newest autoinjector on the market, B-AI, has shown to exhibit better reported outcomes with respect to ease of use and recognition of the end of the injection and other tested indicators.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2020-eular.3698

---

**SAT0635-HPR**

**THE BURDEN OF SCLERODERMA FROM PATIENTS’ PERSPECTIVE**

A. Opinc, O. Brzezińska, J. Makowska. 1 Medical University of Lodz, Department of Rheumatology, Lodz, Poland

**Background:** Scleroderma can significantly impair daily functioning by leading to multi-organ involvement and profound fatigue. Recent studies suggest that objective measures of the disease severity may not necessarily correspond with the patients’ perception.

**Objectives:** To evaluate the degree of disability and fatigue in patients with scleroderma, distinguish the most troublesome activities and assess which clinical symptoms had mostly impacted on daily functioning.

**Methods:** An online questionnaire was created and distributed to English-speaking patients with scleroderma by means of online support groups. The questionnaire contained inquiries about demographic data, clinical symptoms as well as the Scleroderma Health Assessment Questionnaire (SHAQ), comprised of HQI-DI and specific VAS scales) and Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F). Standard and Alternative Disability Indexes (SDI and ADI) were counted based on answers in HQI-DI part. Degrees of disability and fatigue, reflected by SDI, ADI and FACIT-F scores, were compared between subgroup of patients with and without particular clinical symptoms. Responses were analysed statistically.

**Results:** Questionnaire was completed by 85 responders (mean age 48.93±14.4; 98.82% were female). Mean SDI was 1.09±0.66 with 41.18% of patients fulfilling the criteria of mild to moderate difficulty (SDI<1). 50.59% classified as moderate to severe disability (1≤SDI<2) and 8.24% being severely or very severely disabled (SDI≥2). Mean value of ADI was 0.93±0.61. 56.47% of responders needed aid of the caregivers while gripping/opening, 31.76% while reaching and 29.41% while running errands and chores. Most frequently used facilitating devices included devices for gripping/opening (92.94%) and for maintaining hygiene (21.18%). Mean value of overall disease severity was estimated by VAS as 52.06±0.66. The mean values of VAS assessing the impact on daily living were respectively 48.16±29.28 for pain related to the disease, 43.34±34.94 for Raynaud’s, 41.86±34.59 for gastrointestinal problems, 31.60±31.38 for breathing difficulties and 20.85±33.47 for finger ulcers. Mean FACIT-F score was 23.82±11.88 yet 71.76% of patients fulfilled the criteria of severe fatigue. Both SDI and ADI correlated with FACIT-F score (respectively r=-0.5684, p<0.0001 and r=-0.5711, p<0.0001). SDI, ADI and FACIT-F correlated with VAS scores for overall disease severity, pain, gastrointestinal and breathing problems. Patients with symptoms such as arthralgia, muscle weakness, dysphagia, blurred vision, hair loss, unintentional weight loss and hoarseness were statistically more disabled and fatigued as compared to patients without such symptoms. Responders with skin ulcers/non-healing wounds (other than finger ulcers), Raynaud’s or erythema/rash were more disabled than responders without such symptoms, yet no differences were observed in the degree of fatigue.

**Conclusion:** Majority of patients with scleroderma are moderately to severely disabled yet cope with the impairments with the widespread use of facilitating devices or aid of caregivers. Profound fatigue, observed in the majority of patients, may contribute to the high overall perception of disease severity.

**References:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2020-eular.3797

---

**SAT0636-HPR**

**PATIENT EXPERIENCE WITH THE PRESCRIPTION, INFORMATION AND USE OF METHOTREXATE**

T. Oton, L. Carmona, J. L. Andréu Sánchez. 1 InMuse, Instituto de Salud Musculoesquelética, Madrid, Spain; 2 Rheumatology Department. Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain

**Background:** Methotrexate (MTX) is currently a mainstream drug in the treatment of rheumatic diseases. However, the response to MTX is not universal and
T. Garen, O. Palm, B. Gudbrandsson.

Background: Takayasu arteritis (TAK) is a rare vasculitis of large vessels in young women. We have previously reported a point prevalence of 25.6/100,000.

The disease most prevalently limited to the aortic arch and its branches (Type 1) among North Europeans. Early symptoms of TAK include fever, myalgia and loss of appetite. Later, the inflammation of blood vessel may lead to irreversible vascular damage and ischemic symptoms with claudication of the extremities. We have recently found that TAK may reduce life expectancy, mainly due to cardiovascular complications. The median age among those deceased was only 58 years. These findings clearly indicate that TAK may have severe impact on the wellbeing of the patients and their physical capacity.

It is widely accepted to include patients’ perspectives related to their health condition and treatment to better understand the burden of the disease and the impact on their daily life activities. However, studies of health-related quality of life (HRQoL) in TAK have rarely been undertaken, and we are not aware of any studies from the Northern part of Europe.

Objectives: (i) To compare HRQoL in Norwegian TAK with age– and sex matched Norwegian normative data. (ii) To assess patients reported disease symptoms and to evaluate the degree of functional limitation on daily activities and physical capacity. (iii) To evaluate the impact of disease symptoms on HRQoL and functional status.

Methods: Patients with TAK from "The Norwegian Systemic Connective Tissue Disease and Vasculitis Registry" (NOSVAR) were included. All patients had to fulfill the American College of Rheumatology classification criteria and/or the modified Ishikawa diagnostic criteria for TAK and return three sets of questionnaires:

-module of functional limitation on daily activities and physical capacity
-module of disease symptoms
-module of patients reported disease symptoms.

Results: Three focus groups were conducted, with a total of 12 participants, of whom eight were women, seven had rheumatoid arthritis, three had psoriatic arthritis, one had spondyloarthritis, and one had systemic lupus erythematosus. All patients reported an adequate adherence to treatment. The barriers identified were: information in the leaflet, technical language in the consults, difficult access to doctor’s appointment, social environment, side effects and the subcutaneous device. As facilitators, the following aspects were discussed: good disposition of the physician, reliable graphic information, role of associations and partners support.

The unmet needs detected were: problems with travelling, protocols for eventualities, absence of a plan of care, neglection of "non-physical" symptoms, disinformation on side effects and training in complementary aspects.

Conclusion: Getting reliable information was the main barrier identified. The environment and side effects may also negatively impact on adherence. Shared decision making is a goal to be achieved in the future in these patients.

Disclosures of Interests: Teresa Oton Consultant of: Novartis Farmaceutica, SA, Pfizer, U. of Ottawa, Canada; Dohme España, S.A., Roche Farma, S.A, Sanofi Aventis, AbbVie Spain, S.L.U., and Laboratorios Gobo Pharma, SA (All through institution), Loreto Carmona Grant/research support from: Novartis Farmaceutica, SA, Pfizer, S.L.U., Merck Sharp & Dohme España, S.A., Roche Farma, S.A, Sanofi Aventis, AbbVie Spain, S.L.U., and Laboratorios Gobo Pharma, SA (All through institution), José Luis Andreni Sánchez: None declared

DOI: 10.1136/annrheumdis-2020-eular.4059